Open Beta
TREN
MetriLume
TREN

US marketsBTAIQ

SEC-sourced researchBeta

BTAIQ

BioXcel Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001720893
Exchange
OTC
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Sep 1, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 2,266,000.0000 USD; December 2025: 642,000.0000 USD2.3M USD0 USD0December 2024December 2025
BTAIQ · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20242,266,000.0000Mar 27, 2026
December 2025642,000.0000Mar 27, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025642,000.0000-69,897,000.0000-57,615,000.000044,916,000.0000140,379,000.0000Mar 27, 2026
December 20242,266,000.0000-59,599,000.0000-72,027,000.000038,338,000.0000131,439,000.0000Mar 27, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$642KDecember 2025Mar 27, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$2.27MDecember 2024Mar 27, 202610-K
Net incomeNetIncomeLoss-$69.9MDecember 2025Mar 27, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$57.62MDecember 2025Mar 27, 202610-K
Total assetsAssets$44.92MDecember 2025Mar 27, 202610-K
Total liabilitiesLiabilities$140.38MDecember 2025Mar 27, 202610-K

New filings

Explore methodology ↗